Zentalis Pharmaceuticals, Inc. Class Action Lawsuit - ZNTL

Company
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)
Class Period
August 1, 2019 - August 1, 2024

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

Zentalis announced on June 18, 2024, that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC)." Following this news, Zentalis's stock price fell over 50% on June 18, 2024.

Eligibility

In order to be eligible to join the ZNTL class action lawsuit, you must have incurred a loss on shares of Zentalis purchased during the class period listed above.

TOP